Item 1A. RISK FACTORS
3K characters. Original on sec.gov ·
Item 1A. RISK FACTORS
There have been no material changes to the risk factors disclosed in our annual report on Form 10-K for the year ended December 31, 2025.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Issuer Purchases of Equity Securities
The following table discloses purchases of shares of our common stock made by us or on our behalf during the third quarter of 2026.
| Period | Total Number of Shares Purchased (a) | Average Price Paid per Share (b) | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs (c) | ||||||||||||||||||||||||||||
| July 2026 | 4,071 | $308.80 | — | $6.4 billion | ||||||||||||||||||||||||||||
| August 2026 | 3,042,477 | $334.89 | 3,042,337 | $5.4 billion | ||||||||||||||||||||||||||||
| September 2026 | 6,010,390 | $389.63 | 6,008,233 | $3.0 billion | ||||||||||||||||||||||||||||
| Total | 9,056,938 | $371.20 | 9,050,570 | $3.0 billion |
(a)The shares reported in this column include 6,368 shares related to our purchases of shares from participants in our stock-based compensation plans in connection with the vesting of restricted stock and other stock compensation transactions in accordance with the terms of our stock-based compensation plans.
(b)The average price paid per share reported in this column excludes brokerage commissions and a one percent excise tax on share purchases.
(c)On February 25, 2026, we announced that our Board authorized us to purchase shares of our outstanding common stock for a total cost of up to $2.5 billion with no expiration date, and we completed all authorized share purchases under this program during the third quarter of 2026. On July 16, 2026, we announced that our Board authorized us to purchase shares of our outstanding common stock for a total cost of up to $5.0 billion with no expiration date. As of September 30, 2026, we had $3.0 billion remaining available for purchase under the July 2026 Program. On October 27, 2026, our Board authorized us to purchase shares of our outstanding common stock for a total cost of up to $10.0 billion with no expiration date, which is in addition to the amount remaining under the July 2026 Program.
Previous: Item 4. CONTROLS AND PROCEDURES · Next: Item 5. OTHER INFORMATION